China State Administration for Market Regulation enacted new anti-bribery rules for pharma and medical device firms. Starting from January 10, 2025, China has introduced a regulation to govern and limit risks of commercial bribery among pharmaceutical and medical device companies, including foreign entities operating in Chinese market.
The Guidelines identify nine high-risk areas and places primary responsibility on firms to prevent misconduct, emphasizing roles and tasks of MAHs and CROs. Companies must include anti-bribery clauses in contracts, establish compliance systems, and ensure transparency and whistleblower protection.